PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial
PDS Biotechnology Corporation (PDSB)
Last pds biotechnology corporation earnings: 11/7 06:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
60% of evaluable patients demonstrated a clinical response Clinical activity observed at all dose levels Data support previously reported in-vivo induction of active HPV-specific (granzyme B-inducing) CD8+ (killer) T-Cells in patients Plan to initiate three Phase 2 studies for PDS0101 starting in 1Q 2020 BERKELEY HEIGHTS, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immuno-oncology company pioneering the development of novel immunotherapies, today announced that it has reviewed limited available patient clinical outcome data from its previously reported Phase 1 study. In the study, 60% of evaluable patients had a clinical response (as defined below). The primary focus of the study was safety and evaluation of immune biomarkers resulting from administration of Versamune®-based PDS0101 in patients with cervical intraepithelial neoplasia (CIN) infected with multiple high-risk, can
Show less
Read more
Impact Snapshot
Event Time:
PDSB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PDSB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PDSB alerts
High impacting PDS Biotechnology Corporation news events
Weekly update
A roundup of the hottest topics
PDSB
News
- Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround [Yahoo! Finance]Yahoo! Finance
- PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]Yahoo! Finance
- PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial ResultsGlobeNewswire
PDSB
Earnings
- 11/14/24 - In-Line
PDSB
Sec Filings
- 11/14/24 - Form 10-Q
- 11/14/24 - Form 8-K
- 10/2/24 - Form 8-K
- PDSB's page on the SEC website